Compare ATRO & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATRO | SUPN |
|---|---|---|
| Founded | 1968 | 2005 |
| Country | United States | United States |
| Employees | 2700 | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.8B |
| IPO Year | N/A | 2010 |
| Metric | ATRO | SUPN |
|---|---|---|
| Price | $72.72 | $48.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $86.00 | $61.60 |
| AVG Volume (30 Days) | 861.8K | ★ 909.5K |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $392,755,000.00 |
| Revenue This Year | $14.92 | $22.70 |
| Revenue Next Year | $8.81 | $19.14 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $27.27 | $32.21 |
| 52 Week High | $99.89 | $59.68 |
| Indicator | ATRO | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 41.59 | 57.13 |
| Support Level | $71.41 | $47.48 |
| Resistance Level | $80.68 | $52.36 |
| Average True Range (ATR) | 4.24 | 1.59 |
| MACD | -1.28 | 0.50 |
| Stochastic Oscillator | 17.64 | 59.27 |
Astronics Corporation is a provider of technologies to the aerospace, defense, and electronics industries, offering high-performance electrical power generation and distribution systems, motion systems, lighting and safety systems, avionics products, systems certification, aircraft structures, and automated test systems. The company operates through two reportable segments, Aerospace and Test Systems. The Aerospace segment designs and manufactures products for the aerospace and defense industry and generates the majority of revenue, while the Test Systems segment designs, develops, manufactures, and maintains automated test systems for the aerospace and defense, communications, and mass transit industries. The company derives the majority of its revenue from the United States.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.